Highlights TetraLogic Pharmaceuticals Corporation

Equities

TLOG

US88165U1097

Delayed OTC Markets Other stock markets 19:23:16 28/05/2024 BST			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-99.00%

2020	Medivir AB Renegotiates its agreement with TetraLogic Pharmaceuticals Corporation	CI
2017	TetraLogic Pharmaceuticals Corporation Appoints Alexandre Zyngier to Board of Directors and Management	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medivir AB Renegotiates its agreement with TetraLogic Pharmaceuticals Corporation	11/12/20	CI
Medivir AB (OM:MVIR B) completed the acquisition of substantially all the assets of TetraLogic Pharmaceuticals Corporation.	28/12/16	CI
Medivir AB (OM:MVIR B) entered into a definitive asset purchase agreement to acquire substantially all the assets of TetraLogic Pharmaceuticals Corporation for approximately $170 million.	01/11/16	CI
TetraLogic Pharmaceuticals Corporation Announces Results of the Interim Analyses of Two Clinical Studies	06/01/16	CI
TetraLogic Pharmaceuticals Corporation Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Provides Update on SHAPE Alopecia Areata Program	04/11/15	CI
TetraLogic Pharmaceuticals Corporation Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015	05/08/15	CI
TetraLogic Pharmaceuticals Corporation Provides Update on Hepatitis B Clinical Program	20/07/15	CI
TetraLogic Pharmaceuticals Mulls Acquisitions	30/04/15	CI
TetraLogic Announces Publication of Two Papers Describing Birinapant's Preclinical Activity in Chronic Hepatitis B	21/04/15	CI
TetraLogic Pharmaceuticals Corporation and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA(R) (Pembrolizumab) in Solid Tumors	20/04/15	CI
TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA(R) (pembrolizumab) in Solid Tumors	20/04/15	CI
Tetralogic Pharmaceuticals Corporation Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Clinical Update	26/02/15	CI
TetraLogic Files Shelf Registration; Mulls Acquisitions	02/01/15	CI
TetraLogic Pharmaceuticals Corporation Announces Initiation of Randomized Phase 2 Clinical Trial of Shape in Subjects with Cutaneous T-Cell Lymphoma	18/12/14	CI
TetraLogic Pharmaceuticals Corporation Provides Update on Ovarian Cancer Study	16/12/14	CI
TetraLogic Pharmaceuticals Corporation Announces Results of Preclinical Studies in Hepatitis B	10/11/14	CI
TetraLogic Pharmaceuticals Corporation Reports Un-Audited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014	05/11/14	CI
TetraLogic Seeks Acquisitions	17/06/14	CI
TetraLogic Pharmaceuticals Announces Selection of Phase 2 Dose for Randomized Clinical Study of Birinapant in Combination with Azacitidine in Naive Patients with Higher Risk Myelodysplastic Syndromes	27/05/14	CI
TetraLogic Pharmaceuticals Corporation to Present Data from its Clinical Investigation of SHAPE at the Annual Society of Investigative Dermatology Meeting	05/05/14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights TetraLogic Pharmaceuticals Corporation

Equities

TLOG

US88165U1097

Highlights

Filters